Cite
HARVARD Citation
Halmos, B. et al. (2019). Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). Lung cancer. pp. 103-111. [Online].